Acute Improvement of Glucose Variability by Oral Semaglutide (Rybelsus) and Low Carbohydrate Diet (LCD) In Type 2 Diabetes (T2D) Patient with Ophthalmic Operation

Bando H, Okada M, Iwatsuki N, Sakamoto K and Ogawa T

Published on: 2022-08-08

Abstract

Background: Oral semaglutide (Rybelsus) has been in focus as glucagon-like-peptide 1 receptor agonist (GLP1-RA).

Case presentation: Patient is 40-year-old male with diagnosed as type 2 diabetes (T2D). He complained of blurred vision in April 2022, and showed HbA1c 12.0%. He was transferred to university hospital for ophthalmic operation of proliferative vitreoretinopathy and our clinic for diabetic control. He was initiated Rybelsus 3mg/day and super-low carbohydrate diet (LCD) associated with normalized glucose profile in short period.

Discussion: This case showed satisfactory clinical efficacy for HbA1c 8.7% and 6.6% in 4 and 8 weeks, and weight reduction 6kg for 3 months.